Could Daily Monitoring of Fibrin Related Markers Help Suspect a Thrombotic Event in COVID-19 Patients? A Prospective Pilot Study

1Université catholique de Louvain, CHU UCL Namur, Namur Thrombosis and Hemostasis Center (NTHC), Namur Research Institute for Life Sciences (NARILIS), Hematology Laboratory, Yvoir, Belgium 2Université catholique de Louvain, CHU UCL Namur, Namur Thrombosis and Hemostasis Center (NTHC), Namur Research Institute for Life Sciences (NARILIS), Anesthesiology Department, Yvoir, Belgium 3Université catholique de Louvain, CHU UCL Namur, Intensive Care Department, Yvoir, Belgium 4Division of Angiology and Hemostasis Geneva Platelet Group, Departement of Medicine, Université de Genève et Hôpitaux Universitaires de Genève, Geneva, Switzerland

[1]  S. Laporte,et al.  Prothrombotic disturbances of hemostasis of patients with severe COVID-19: A prospective longitudinal observational study , 2020, Hämostaseologie.

[2]  Y. Komiyama,et al.  Characterization of fibrin/fibrinogen degradation products reagents and their utility in critical care patients with enhanced fibrinolysis , 2020, International journal of laboratory hematology.

[3]  Melanie S Wooten,et al.  Retrospective Analyses Associate Hemostasis Activation Biomarkers With Poor Outcomes in Patients With COVID-19 , 2020, American journal of clinical pathology.

[4]  S. Laporte,et al.  Prothrombotic hemostasis disturbances in patients with severe COVID-19: Individual daily data , 2020, Data in Brief.

[5]  Emma M Schatoff,et al.  D-dimer cut-off points and risk of venous thromboembolism in adult hospitalized patients with COVID-19 , 2020, Thrombosis Research.

[6]  J. Thachil,et al.  Biomarkers for the prediction of venous thromboembolism in critically ill COVID-19 patients , 2020, Thrombosis Research.

[7]  T. Soumagne,et al.  Elevated D-dimers and lack of anticoagulation predict PE in severe COVID-19 patients , 2020, European Respiratory Journal.

[8]  L. Alberio,et al.  Utility of D-dimers and intermediate-dose prophylaxis for venous thromboembolism in critically ill patients with COVID-19 , 2020, Thrombosis Research.

[9]  J. Mascarenhas,et al.  Admission D-dimer levels, D-dimer trends, and outcomes in COVID-19 , 2020, Thrombosis Research.

[10]  D. Gommers,et al.  Incidence of thrombotic complications in critically ill ICU patients with COVID-19 , 2020, Thrombosis Research.

[11]  G. Lippi,et al.  D-dimer is Associated with Severity of Coronavirus Disease 2019: A Pooled Analysis , 2020, Thrombosis and Haemostasis.

[12]  Y. Hu,et al.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.

[13]  M. Refaai,et al.  The Clinical Significance of Fibrin Monomers , 2018, Thrombosis and Haemostasis.

[14]  J. Thachil,et al.  A re‐evaluation of the D‐dimer cut‐off value for making a diagnosis according to the ISTH overt‐DIC diagnostic criteria: communication from the SSC of the ISTH , 2018, Journal of thrombosis and haemostasis : JTH.

[15]  B. Sangro,et al.  Radioembolization of hepatocellular carcinoma activates liver regeneration, induces inflammation and endothelial stress and activates coagulation , 2015, Liver international : official journal of the International Association for the Study of the Liver.

[16]  C. Downey,et al.  The clinical utility of fibrin-related biomarkers in sepsis , 2013, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[17]  Martin Borggrefe,et al.  Use of soluble fibrin antigen instead of D-dimer as fibrin-related marker may enhance the prognostic power of the ISTH overt DIC score , 2004, Thrombosis and Haemostasis.

[18]  M. Hennerici,et al.  Changes in coagulation and fibrinolysis markers in acute ischemic stroke treated with recombinant tissue plasminogen activator. , 1999, Stroke.

[19]  C. Dempfle,et al.  The Use of Soluble Fibrin in Evaluating the Acute and Chronic Hypercoagulable State , 1999, Thrombosis and Haemostasis.